Protagonist Therapeutics Inc (NASDAQ:PTGX) has been assigned a consensus rating of “Hold” from the six research firms that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $37.00.
A number of equities analysts have commented on PTGX shares. BMO Capital Markets lowered their price objective on Protagonist Therapeutics from $45.00 to $40.00 and set an “outperform” rating on the stock in a research note on Thursday, October 19th. Zacks Investment Research lowered Protagonist Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 18th. BidaskClub upgraded Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. Finally, Stifel Nicolaus started coverage on Protagonist Therapeutics in a research note on Monday. They set a “buy” rating and a $32.00 price objective on the stock.
Protagonist Therapeutics (PTGX) opened at $19.23 on Monday. The firm has a market capitalization of $393.82, a P/E ratio of -7.15 and a beta of -1.66. Protagonist Therapeutics has a 52 week low of $8.00 and a 52 week high of $21.68.
In other Protagonist Therapeutics news, insider Dinesh V. Ph D. Patel sold 1,790 shares of the firm’s stock in a transaction on Wednesday, December 20th. The stock was sold at an average price of $19.55, for a total transaction of $34,994.50. Following the transaction, the insider now owns 192,227 shares in the company, valued at approximately $3,758,037.85. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Richard S. Shames sold 3,529 shares of the firm’s stock in a transaction on Friday, December 22nd. The stock was sold at an average price of $20.50, for a total value of $72,344.50. Following the transaction, the insider now owns 3,529 shares in the company, valued at approximately $72,344.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,944 shares of company stock worth $438,629. Corporate insiders own 15.50% of the company’s stock.
Several hedge funds have recently modified their holdings of PTGX. Rhumbline Advisers acquired a new stake in shares of Protagonist Therapeutics in the 2nd quarter valued at $114,000. Bank of Montreal Can boosted its holdings in shares of Protagonist Therapeutics by 1,086.0% in the 4th quarter. Bank of Montreal Can now owns 5,930 shares of the company’s stock valued at $123,000 after purchasing an additional 5,430 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Protagonist Therapeutics by 60.8% in the 3rd quarter. Wells Fargo & Company MN now owns 9,565 shares of the company’s stock valued at $169,000 after purchasing an additional 3,617 shares in the last quarter. Teachers Advisors LLC boosted its holdings in shares of Protagonist Therapeutics by 71.4% in the 2nd quarter. Teachers Advisors LLC now owns 16,218 shares of the company’s stock valued at $183,000 after purchasing an additional 6,757 shares in the last quarter. Finally, California State Teachers Retirement System boosted its holdings in shares of Protagonist Therapeutics by 8.5% in the 2nd quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock valued at $188,000 after purchasing an additional 1,300 shares in the last quarter. 41.86% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “Protagonist Therapeutics Inc (PTGX) Receives Average Rating of “Hold” from Analysts” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/29/protagonist-therapeutics-inc-ptgx-receives-average-rating-of-hold-from-analysts.html.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.